Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison
In these MAICs, atogepant was associated with statistically significant greater reductions in MMDs and monthly acute MUDs, and greater improvements in MSQ v2.1 RFR domain scores versus rimegepant in Japanese patients with migraine.
Authors
- Tsubasa Takizawa (ORCID: https://orcid.org/0000-0003-2605-7200)
- Gina Ahmadyar (ORCID: https://orcid.org/0000-0002-9235-2876)
- Haris Jameel
- Toru Yamazaki (ORCID: https://orcid.org/0000-0002-5124-756X)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Keisuke Suzuki (ORCID: https://orcid.org/0000-0003-0320-8993)
- Emma Tyas (ORCID: https://orcid.org/0009-0002-6984-1425)
- Hisaka Igarashi
- Mamoru Shibata (ORCID: https://orcid.org/0000-0002-2416-4259)
- Noboru Imai (ORCID: https://orcid.org/0000-0002-8745-0391)
- Judy Chen (ORCID: https://orcid.org/0000-0001-9933-987X)
- Naoko Sanno
- Yoichiro Hashimoto
- Molly Duan
- Ifeanyi Ubamadu
Institutions
- Shinawatra University (TH)
- Utrecht University (NL)
- Keio University (JP)
- Fujitsu (Japan) (JP)
- AbbVie (United States) (US)
- Saiseikai Kumamoto Hospital (JP)
- Tokyo Dental College Ichikawa General Hospital (JP)
- ABB (Japan) (JP)
- Shizuoka Red Cross Hospital (JP)
- AbbVie (Japan)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Expert Review of Neurotherapeutics
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1080/14737175.2025.2599853
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00